Last reviewed · How we verify
Active hypertension medical therapy
Blocks the action of angiotensin II at the AT1 receptor
Blocks the action of angiotensin II at the AT1 receptor Used for Hypertension.
At a glance
| Generic name | Active hypertension medical therapy |
|---|---|
| Sponsor | Verve Medical, Inc |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Mechanism of action
This leads to vasodilation and a decrease in blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA. (PHASE3)
- Impact of Multi-component Interventions on Populations With Mental Health Symptoms and High-risk COPD (NA)
- Impact of Multi-Component Interventions on High-Risk COPD Smokers (NA)
- REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription (NA)
- Liraglutide Effect in Atrial Fibrillation (PHASE4)
- DASH Diet in Heart Failure Outpatients (NA)
- Impact on Physical Activity of Coronary Patients in Phase 3 of a Therapeutic Consolidation Educational Program Involving a "Patient Partner" Associated With a Healthcare Professional. (NA)
- Nephrospec Switzerland (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active hypertension medical therapy CI brief — competitive landscape report
- Active hypertension medical therapy updates RSS · CI watch RSS
- Verve Medical, Inc portfolio CI